SCHEMBL10245901

SCHEMBL10245901

CCCCNC(=O)c1ccnc2ncccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.56
TSHR P16473 1/20 0.56
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
NAAA Q02083 2/20 0.46
ASAH1 Q13510 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HCRTR1 O43613 1/20 0.43
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243020 0.83 HTT (0.60) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL10244776 0.82 NSD2 (0.64) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL161560 0.78 HTT (0.66) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL6358755 0.78 HTT (0.66) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL31047590 0.77 NSD2 (0.61) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL31047570 0.77 NSD2 (0.61) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL10244761 0.77 SMN1; SMN2 (0.49) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL10245917 0.75 TSHR (0.60) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL9277985 0.74 TSHR (0.69) HTTTSHRHPGDSMN1; SMN2NAAA
SCHEMBL6495739 0.74 HTT (0.58) HTTTSHRHPGDSMN1; SMN2NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 HTT 868/4885TSHR 1567/4885HPGD 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.